I know a lot about Fovista and this space. And I have a decent amount of info on both Novartis and Eylea product....And the upcoming Roche product that at least on paper is very attractive.....And a good amount of what sort of treatments big Pharma's are looking to acquire for the next chapter of Anti-Vegf treatments and I can 100% tell you its not a combination therapies....
And yes, knowing the risk benefit is crucial on the decision marking ....
GLTAH
Ann: Opthea Finalizes Ph 3 Study Designs and Startup Activities, page-37
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
45.0¢ |
Change
0.010(2.27%) |
Mkt cap ! $553.9M | |||
| Open | High | Low | Value | Volume |
| 44.0¢ | 45.5¢ | 43.5¢ | $417.7K | 934.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9400 | 44.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.5¢ | 26000 | 1 |
View Market Depth
| Last trade - 16.10pm 15/08/2024 (20 minute delay) ? |
| OPT (ASX) Chart |